Role of metal ions in the Aβ oligomerization in Alzheimer's disease and in other neurological disorders

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 500-507

  Drago, D ^a   Bolognin, S ^a   Zatta, P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Aggregation; Alzheimer's disease; Amyloid; Metal ions; Oligomers

Indexed keywords

ALUMINUM; AMYLOID; AMYLOID BETA PROTEIN; ATAXIN 1; COPPER ION; HUNTINGTIN; IRON; METAL ION; PRION PROTEIN; ZINC ION;

ALZHEIMER DISEASE; HUMAN; MICROARRAY ANALYSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ALUMINUM; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; METALS; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION;

EID: 58049209924     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898479     Document Type: Review

References (117)

1. Thomas PJ, Qu BH, Pederson PL. Defective protein folding as a basis of human disease. Trends Biochem Sci 20: 456-459 (1995).
2. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678-699 (2003).
3. Dobson CM. The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356: 133-145 (2001).
4. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739: 5-25 (2004).
5. Monti M, Garolla di Bard BL, Calloni G, Chiti F, Amoresano A, Gianpietro R, et al. The regions of the sequence most exposed to the solvent within the amyloidogenic state of a protein initiate the aggregation process. J Mol Biol 336: 253-262 (2004).
6. Hardy J, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185 (1992).
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
8. Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN, et al. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 50: 397-409 (2004).
9. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26 (2002).
10. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739: 198-210 (2005).
11. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639 (2004).
12. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft, LaDu MJ, et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053 (2002).
13. Kayed R, Head E, Thompson JL, Mclntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489 (2003).
14. Glabe CG. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci 29: 542-547 (2004).
15. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-862 (1999).
16. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. Proc Natl Acad Sci USA 101: 16180-16185 (2000).
17. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann Rev Neurosci 26: 267-298 (2003).
18. Necula M, Kayed R, Milton S, Glabe C. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are indipendent and distinct. J Biol Chem 282: 10311-10324 (2007).
19. Deshpande A, Mina E, Glabe CG, Busciglio J. Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011-6018 (2006).
20. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from A beta (1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998).
21. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924: 133-140 (2002).
22. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimr's-related amyloid beta oligomers. J Neurosci 24: 10191-200 (2004).
23. Chang L, Bakhos L, Wang Z, Venton DL, Klein WL. Femtomole immunodetection of synthetic and endogenous amyloid-βoligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci 20: 305-313 (2003).
24. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100: 10417-22 (2003).
25. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102: 2273-2276 (2005).
26. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-β oligomers. Their production, toxicity, and therapeutic inhibition. Biochem Soc Trans 30: 552-557 (2002).
27. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84 (2005).
28. Lesnè S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357 (2006).
29. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role of trimers. J Physiol 572: 447-492 (2006).
30. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol 168: 184-194 (2006a).
31. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal Profile of amyloid-β(Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 281, 1599-1604 (2006b).
32. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-224 (2001).
33. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 8: 499-509 (2007).
34. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39: 409-421 (2003).
35. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's diseaserelated cognitive deficits in transgenic mice. Neuron 45: 675-688 (2005).
36. Gyure KA, Duhram R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489-492 (2001).
37. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59: 332-345 (2007).
38. Cheng IH, Scearce-Levie K, Legleiter J, Palopp JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282: 23818-23828 (2007).
39. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, et al. Certain inhibitors of synthetic amyloid β-peptide, Aβfibrillogenesis block oligomerization of natural Aβand thereby rescue long-term potentetion. J Neurosci 25: 2455-2462 (2005).
40. Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, Iwamoto T, et al. A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-β oligomers complexes. J Neurochem 98: 57-67 (2006).
41. Liu Y, Scubert D. Treating Alzheimer's disease by inactivating bioactive amyloid Beta Peptide. Curr Alzheimer Res 3: 129-135 (2006).
42. Hong HS, Maezawa I, Yao N, Xu B, Diaz-Avalos R, Rana S, et al. Combining the rapid MTT formazan assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβoligomer-induced cytotoxicity. Brain Res 1130: 223-234 (2007).
43. Zatta P, Lucchini R, Van Rensburg SJ, Taylor A. The role of metals in neurodegenerative processes: aluminum, manganese and zinc. Brain Res Bull 62: 15-28 (2003).
44. Zatta P. Metal ions and neurodegenerative disorders. (Ed: Zatta P), World Scientific, Singapore, London 1-511 (2003).
45. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, et al. Metal exposure and Alzheimer's pathogenesis. J Struct Biol 155: 45-51 (2006).
46. Lovell MA, Ehmann WD, Markesbery WR. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann Neurol 33: 36-42 (1993).
47. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52 (1998).
48. Beauchemin D, Kisilevsky R. A method based on ICP-MS for the analysis of Alzheimer's amyloid plaques. Anal Chem 70: 1026-1029 (1998).
49. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochem 42: 2768-2773 (2003).
50. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role of bound transition metals. J Neurochem 74: 270-279 (2000).
51. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 852, 274-278 (2000).
52. Miu AC, Benga O. Aluminum and Alzheimer's disease: a new look. J Alzheimer Dis 10: 179-201 (2006).
53. Morgan DM, Dong J, Jacob J, Lu K, Apkarian RP, Thiyagarajan P, et al. Metal switch for amyloid formation: insight into the structure of the nucleus. J Am Chem Soc 124: 12644-12645 (2002).
54. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214 (2003).
55. House E, Collingwod J, Khan A, Korchazkina O, Berthon G, Exley C, et al. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimer Dis 6: 291-301 (2004).
56. Ricchelli F, Drago D, Filippi B, Tognon G, Zatta P. Aluminum-triggered structural modifications and aggregation of beta-amyloids. Cell Mol Life Sci 62: 1724-1733 (2005).
57. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-β in Alzheimer's disease. Int J Exp Pathol 86: 147-159 (2005).
58. Cherny RA, Legg JT, Mclean CA, Fairlie DP, Huang X, Atwood SC, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 274: 23223-23228 (1999).
59. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer' s disease transgenic mice. Neuron 30: 665-76 (2001).
60. Opazo C, Barria MI, Ruiz FH, Inestrosa NC. Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. Biometals 16: 91-98 (2003).
61. Yoshiike Y, Tanemura K, Murayama O, Akagi T, Murayama M, Sato S, et al. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J Biol Chem 276: 32293-32299 (2001).
62. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI, et al. Trace elements contamination initiates the apparent autoaggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem 9: 954-60 (2004).
63. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 61: 1171-4 (1993).
64. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 273: 12817-26 (1998).
65. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, et al. Characterization of copper interactions with Alzheimer amyloid beta peptides identification of an attomolar-affinity copper binding site on amyloid beta 1-42. J Neurochem 75: 1219-33 (2000).
66. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu (II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxidase production and metal reduction. J Biol Chem 274: 37111-6 (1999).
67. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, et al. Amyloid-β: a chameleon walking in two worlds: a reviw of the trophic and toxic properties of amyloid-βBrain Res Rev 43: 1-16 (2003).
68. Savory J, Jagannatha Rao KS, Huang Y, Letada PR, Herman MM. Age-related hippocampal changes in Bcl-2:Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminium-induced neurodegeneration: increased susceptibility with aging. Neurotoxicology 20: 805-818 (1999).
69. Banks WA, Banks AJ, Zatta P. The blood brain-barrier in aluminum toxicity and Alzheimer's disease. In: Non-neuronal Cells in Alzheimer's disease, (Eds: Zatta P & Nicolini M), World Scientific, Singapore 1-12 (1995).
70. Yokel RA, Wilson M, Harris WR, Halestrap AP. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood-brain barrier transport. Brain Res 930: 101-110 (2002).
71. Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 10: 223-53 (2006).
72. Candy JM, Klinowski J, Perry RH, Perry EK, Fairbairn A, Oakley AE, et al. Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet 1: 354-357 (1986).
73. Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: laser microprobe (LAMMA) study. Ann Neurol 31: 286-92 (1992).
74. Zatta P. Aluminum binds to the hyperphosphorilated tau in Alzheimer's disease: a hypothesis. Med Hypotheses 44: 169-172 (1995).
75. Perl DP, Brody AR. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208: 297-9 (1980).
76. Wisniewski HM, Wen GY. Aluminium and Alzheimer's disease. Ciba Found Symp 169: 142-54 (1992).
77. Chafi AH, Hauw JJ, Rancurel G, Berry JP, Galle C. Absence of aluminum in Alzheimer's disease brain tissue: electron microprobe and ion microprobe studies. Neurosci Lett 123: 61-4 (1991).
78. Landsberg JP, McDonald B, Watt F. Absence of aluminum in neuritic plaque cores in Alzheimer's disease. Nature 360: 65-68 (1992).
79. Alfrey AC, LeGrendre GR, Kaehny WD. The dialysis encephalophaty syndrome. Possible aluminum intoxication. N Engl J Med 294: 184-188 (1976).
80. Alfrey AC. Aluminum metabolism. Kidney Int Suppl 18: S8-S11 (1986).
81. Reusche E. In: Aluminum and central nervous system morphology in hemodialysis. (Ed: Zatta P), 'Metal ions in neurological disorders' World Scientific, Singapore, London 1-511 (2003).
82. Jacqmin H, Commenges D, Letenneur L, Barberger-Gateau P, Dartigues JF. Components of drinking water and risk of cognitive impairments in the elderly. Am J Epidemiol 139: 48-57 (1994).
83. McLachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 46: 401-405 (1996).
84. Campbell A, Becaria A, Lahiri DK, Sharman K, Bondy SC. Chronic exposure to Al in drinking water increases inflammatory parameters selectively in the brain. J Neurosci Res 75: 565-572 (2004).
85. Zatta P. Aluminum and Alzheimer's disease: A vexata questio between uncertain data and a lot of imagination. J Alzheimer Dis 10: 33-37 (2006).
86. Moore PB, Day JP, Taylor GA, Ferrier IN, Fifield LK, Edwardson JA. Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement Geriatr Cogn Disord 11: 66-69 (2000).
87. Amstrong RA, Anderson J, Cowburn JD, Cox J, Blair JA. Aluminum administered in drinking water but not in diet influences biopterin metabolism in rodent. Biol Chem Hoppe Seyler 373: 1075-8 (1992).
88. Whitehead MW, Farrar G, Christie GL, Blair JA, Thompson RP, Powell JJ, et al. Mechanisms of aluminum absorption in rats. Am J Clin Nutr 65: 1446-1452 (1997).
89. Cricthon RR, Florence A, Ward RJ. Aluminum and iron in the brain-prospects for chelation. Coord Chem Rev 228: 365-371 (2002).
90. Zatta P. Controversial aspects of aluminium (III) accumulation and subcompartmentation in Alzheimer's disease. J Trace Elements Med Biol 10: 120-128 (1993).
91. Munoz DG. Is exposure of aluminum a risk factor for the development of Alzheimer's disease? Arch Neurol 55: 737-739 (1998).
92. Bala Gupta V, Anitha S, Hedge ML, Zecca L, Garruto MR, Ravid R, et al. Aluminium in Alzheimer's disease: are we still at a crossroad? Cell Mol Life Sci 62: 143-158 (2005).
93. Walton JR. Aluminum in hippocampal neurons from humans with Alzheimer's disease. Neurotoxicity 27: 385-394 (2006).
94. Domingo JL. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. J Alzheimer Dis 10: 331-341 (2006).
95. Kawahara M, Muramoto K, Kobayashi K, Mori H, Kuroda Y. Aluminum promotes the aggregation of Alzheimer's amyloid beta-protein in vitro. Biochem Biophys Res Commun 198: 531-535 (1994).
96. Evans P, Harrington C. Aluminosilicate particulate and beta-amyloid in vitro interactions: a model of Alzheimer plaque formation. Biochem Soc Trans 26: S251 (1998).
97. Praticò D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VM, et al. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J 16: 1138-40 (2002).
98. Kawahara M, Kato M, Kuroda Y. Effects of aluminium on the neurotoxicity of primary cultured neurons and on the aggregation of beta-amyloid protein. Brain Res Bull 55: 211-217 (2001).
99. Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J Alzheimer Dis 8: 171-82 (2005).
100. Banks WA, Niehoff ML, Drago D, Zatta P. Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res 1116: 215-221 (2006).
101. Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, Lee JP, et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39: 6288-95 (2000).
102. Kelly JW. Mechanisms of amyloidogenesis. Nat Struct Biol 7: 824-6 (2000).
103. Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol 2: e321 (2004).
104. Gales L, Cortes L, Almeida C, Melo CV, do Carmo Costa M, Maciel P, et al. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. Mol Biol 353: 642-54 (2005).
105. Ellisdon AM, Pearce MC, Bottomley SP. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol 368(2): 595-605 (2007).
106. Ricchelli F, Buggio R, Drago D, Forloni G, Negro A, Tognon G, et al. Aggregation/Fibrillogenesis of recombinant human prion protein and Gestmann-Straussler-Scheinker disease peptides in the presence of metal ions. Biochemistry 45: 6724-32 (2006).
107. Ricchelli F, Fusi P, Tortora P, Valtorta M, Riva M, Tognon G, et al. Destabilization of non- pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis. Int J Biochem Cell Bio 39: 966-977 (2007).
108. 1-42-aluminum complex in Alzheimer's disease. Int J Biochem Cell Biol 40(4): 731-46 (2008).
109. Drago D, Folin M, Baiguera S, Tognon G, Ricchelli F, Zatta P. Comparative effects of Aβ(1-42)-Al complex from rat and human on rat endothelial cells. J Alzheimers Dis 11: 33-44 (2007).
110. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622 (2003).
111. 1-42 on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res (2008) in press. DOI 10.1089/rej.2008.0761
112. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280: 17294-17300 (2005).
113. Casley C, Canevari L, Land J, Clark J, Sharpe M. β-amyloid inhibits mitochondrial respiration and key enzyme activities. J Neurochem 80: 91-100 (2002).
114. Moreira PI, Santos MS, Moreno AM, Seica R, Oliveira CR. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes 52: 1449-56 (2003).
115. Canevari L, Abramov AY, Duchen MR. Toxicity of amyloid β peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res 29: 637-650 (2004).
116. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, et al. Mitochondrial Aβ: a potential role point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19: 2040-2041 (2005).
117. Aleardi AM, Benard G, Augereau O, Malgat M, Talbot JC, Mazat JP, et al. Gradual alteration of mitochondrial structure and function byβ-amyloids: Importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytocrome c release. J Bioenerg Biomembr 37: 207-225 (2005).